Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-28T10:12:51.975Z Has data issue: false hasContentIssue false
  • English
  • Français

Role of T-helper 17 cell related cytokines in laryngeal cancer

Published online by Cambridge University Press:  22 April 2019

T K Muderris ,
F Gul ,
A Doblan ,
M Ergin  and
T Muderris
T K Muderris
Affiliation:
Department of Microbiology, Izmir Ataturk Training and Research Hospital, Izmir, Turkey
F Gul*
Affiliation:
Department of Otorhinolaryngology, Head and Neck Surgery, Yıldırım Beyazıt University School of Medicine, Ankara, Turkey
A Doblan
Affiliation:
Department of Otorhinolaryngology, Head and Neck Surgery, Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkey
M Ergin
Affiliation:
Department of Clinical Biochemistry, Gaziantep 25 Aralık State Hospital, Gaziantep, Turkey
T Muderris
Affiliation:
Department of Otorhinolaryngology, Head and Neck Surgery, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey
*
Author for correspondence: Assistant Prof Fatih Gul, Department of Otorhinolaryngology, Head and Neck Surgery, Yıldırım Beyazıt University School of Medicine, Ankara, Turkey E-mail: [email protected] Fax: +90 3122 912 786
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

To explore the role of T-helper 17 cells and their cascade in the pathogenesis of laryngeal cancer.

Methods

Prospectively, 110 consecutive patients with a suspicious laryngeal lesion were evaluated for serum levels of T-helper 17 cell related interleukins, including interleukins 23, 17A and 22, determined by enzyme-linked immunosorbent assay. The patients were divided into 2 groups after pathological evaluation: 49 patients with malignancy and 61 with benign pathology. Associations between interleukin levels and malignancy were determined via correlation analyses.

Results

Interleukin 17A and 22 levels were significantly higher in the malignancy group than the benign lesion group. Pearson correlation analysis showed that interleukins 17A and 22 acted in a cascade, but interleukin 23 did not. According to predictive values, interleukin 17A levels were 3.87 times and interleukin 22 levels were 1.09 times more likely to be associated with laryngeal cancer. The cut-off values for predicting laryngeal cancer were 3.55 pg/ml for interleukin 17A and 119.82 pg/ml for interleukin 22.

Conclusion

T-helper 17 cell related interleukins are potential biomarkers that may be helpful in diagnosing laryngeal cancer. Moreover, these data may support neutralisation of T-helper 17 cell related cytokine activity, which could be an attractive strategy for treating laryngeal cancer.

Keywords

Th17 CellsLaryngeal NeoplasmIL-17AIL-23
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 133 , Issue 5 , May 2019 , pp. 394 - 398
Copyright
Copyright © JLO (1984) Limited, 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Assistant Prof F Gul takes responsibility for the integrity of the content of the paper

References

1National Cancer Institute. Cancer Statistics Factsheets: Laryngeal Cancer. In: http://seer.cancer.gov/statfacts/html/laryn.html [15 April 2018]Google Scholar
2Stämpfli, MR, Anderson, GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol 2009;9:377–84Google Scholar
3Langowski, JL, Zhang, X, Wu, L, Mattson, JD, Chen, T, Smith, K et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461–5Google Scholar
4Grivennikov, SI, Wang, K, Mucida, D, Stewart, CA, Schnabl, B, Jauch, D et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012;491:254–8Google Scholar
5Li, J, Lau, G, Chen, L, Yuan, YF, Huang, J, Luk, JM et al. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS One 2012;7:e46264Google Scholar
6Schetter, AJ, Nguyen, GH, Bowman, ED. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 2009;15:5878–87Google Scholar
7Coussens, LM, Werb, Z. Inflammation and cancer. Nature 2002;420:860–7Google Scholar
8Mantovani, A, Allavena, P, Sica, A, Balkwill, F. Cancer-related inflammation. Nature 2008;454:436–44Google Scholar
9Balkwill, F, Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–45Google Scholar
10Schwartsburd, PM. Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev 2003;22:95–102Google Scholar
11Philip, M, Rowley, DA, Schreiber, H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433–9Google Scholar
12Seril, DN, Liao, J, Yang, GY, Yang, CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003;24:353–62Google Scholar
13Macarthur, M, Hold, GL, El-Omar, EM. Inflammation and cancer. II. Role of chronic inflammation and cytokine polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004;286:G515–20Google Scholar
14Mayron, R, Grimwood, RE, Siegle, RJ, Camisa, C. Verrucous carcinoma arising in ulcerative lichen planus of the soles. J Dermatol Surg Oncol 1998;14:547–51Google Scholar
15Risch, HA, Howe, GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995;4:447–51Google Scholar
16Karin, M, Cao, Y, Greten, FR, Li, ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301–10Google Scholar
17Wu, S, Rhee, KJ, Albesiano, E, Rabizadeh, S, Wu, X, Yen, HR et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016–22Google Scholar
18Ji, Y, Zhang, W. Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 2010;59:979–87Google Scholar
19Mojtahedi, Z, Khademi, B, Erfani, N, Taregh, Y, Rafati, Z, Malekzadeh, M et al. Serum levels of interleukin-7 and interleukin-8 in head and neck squamous cell carcinoma. Indian J Cancer 2014;51:227–30Google Scholar
20Melinceanu, L, Lerescu, L, Tucureanu, C, Caras, I, Pitica, R, Sarafoleanu, C et al. Serum perioperative profile of cytokines in patients with squamous cell carcinoma of the larynx. J Otolaryngol Head Neck Surg 2011;40:143–50Google Scholar
21Eyigor, M, Eyigor, H, Osma, U, Yilmaz, MD, Erin, N, Selcuk, OT et al. Analysis of serum cytokine levels in larynx squamous cell carcinoma and dysplasia patients. Iran J Immunol 2014;11:259–68Google Scholar
22Melinceanu, L, Sarafoleanu, C, Lerescu, L, Tucureanu, C, Caraş, I, Salageanu, A. Impact of smoking on the immunological profile of patients with laryngeal carcinoma. J Med Life 2009;2:211–18Google Scholar